ImageneBio, Inc. (IMA) SEC filings

IMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30

$3.45−0.27 (-7.26%)

Close on Nov 12, 2026Market cap $39.16MP/E –Yield –

SEC filings

40 of ImageneBio's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	8-K	Nov 9, 2026	Nov 9, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2026	Nov 9, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 5, 2026	SEC EDGAR
Current report	8-K	Aug 5, 2026	Aug 5, 2026	SEC EDGAR
Current report	8-K	Jul 20, 2026	Jul 23, 2026	SEC EDGAR
Current report	8-K	Jun 22, 2026	Jun 26, 2026	SEC EDGAR
Current report	8-K	Jun 16, 2026	Jun 17, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 7, 2026	SEC EDGAR
Current report	8-K	May 7, 2026	May 7, 2026	SEC EDGAR
Proxy statement	DEF 14A	Jun 16, 2026	Apr 30, 2026	SEC EDGAR
Current report	8-K	Apr 12, 2026	Apr 13, 2026	SEC EDGAR
Current report	8-K	Mar 12, 2026	Mar 17, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 10, 2026	SEC EDGAR
Current report	8-K	Mar 10, 2026	Mar 10, 2026	SEC EDGAR
Current report	8-K	Feb 12, 2026	Feb 17, 2026	SEC EDGAR
Current report	8-K	Dec 12, 2025	Dec 18, 2025	SEC EDGAR
Current report	8-K	Nov 19, 2025	Nov 19, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 12, 2025	SEC EDGAR
Current report	8-K	Nov 12, 2025	Nov 12, 2025	SEC EDGAR
Current report	8-K	Nov 1, 2025	Nov 5, 2025	SEC EDGAR
Current report	8-K	Oct 23, 2025	Oct 29, 2025	SEC EDGAR
Current report	8-K	Oct 21, 2025	Oct 22, 2025	SEC EDGAR
Current report	8-K	Oct 10, 2025	Oct 10, 2025	SEC EDGAR
Current report	8-K	Aug 2, 2025	Aug 5, 2025	SEC EDGAR
Current report	8-K	Jul 28, 2025	Aug 1, 2025	SEC EDGAR
Current report	8-K	Jul 25, 2025	Jul 29, 2025	SEC EDGAR
Current report	8-K	Jul 25, 2025	Jul 25, 2025	SEC EDGAR
Current report	8-K	Jul 24, 2025	Jul 24, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Jul 24, 2025	SEC EDGAR
Current report	8-K	Jul 22, 2025	Jul 22, 2025	SEC EDGAR
Current report	8-K	Jul 15, 2025	Jul 16, 2025	SEC EDGAR
Current report	8-K	Jul 15, 2025	Jul 15, 2025	SEC EDGAR
Current report	8-K	Jul 11, 2025	Jul 11, 2025	SEC EDGAR
Current report	8-K	Jul 1, 2025	Jul 1, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 8, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 6, 2025	SEC EDGAR
Current report	8-K	Dec 23, 2024	Dec 23, 2024	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 7, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 8, 2024	SEC EDGAR
Current report	8-K	Jul 8, 2024	Jul 12, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in ImageneBio's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-12 reverse split on Jul 28, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is IMA.

Compare: IMA vs CMPX · IMA vs ARTV · IMA vs SABS · IMA vs PALI · IMA vs INBX

Company	Revenue	Growth
IMA	$800.00K	-77.1%
PALI	$500.00K	–
CMPX	–	–
ARTV	–	–
SABS	–	–
INBX	–	–

Company

Next earnings (est.): Mar 9, 2027, before open
Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 15
Held by institutions: 54.9%
Auditor: PricewaterhouseCoopers LLP
SEC CIK: 1835579

Advertisement
300 × 250

See a number that looks wrong?